| Paroxysmal nocturnal hemoglobinuria
PiaSky vs Empaveli
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Piasky vs Empaveli with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEmpaveli has a higher rate of injection site reactions vs Piasky based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Empaveli but not Piasky, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Piasky
Empaveli
At A Glance
IV infusion / SC injection
Every 4 weeks (maintenance)
Complement C5 inhibitor
SC injection
Twice weekly
C3 complement inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Paroxysmal nocturnal hemoglobinuria
- C3 glomerulopathy
- Immune-complex membranoproliferative glomerulonephritis
Dosing
Paroxysmal nocturnal hemoglobinuria Loading: 1,000 mg (>=40 kg to <100 kg) or 1,500 mg (>=100 kg) IV on Day 1, then 340 mg SUBQ on Days 2, 8, 15, and 22; maintenance 680 mg (>=40 kg to <100 kg) or 1,020 mg (>=100 kg) SUBQ every 4 weeks starting Day 29.
Paroxysmal nocturnal hemoglobinuria 1,080 mg SC twice weekly; adjust to 1,080 mg every three days if LDH >2x ULN.
C3 glomerulopathy, Immune-complex membranoproliferative glomerulonephritis Adults: 1,080 mg SC twice weekly; pediatric patients (12 to <18 years): weight-based dosing from 648 mg to 1,080 mg SC twice weekly based on body weight.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Known serious hypersensitivity reaction to crovalimab or any excipient
- Hypersensitivity to pegcetacoplan or any excipient
- Unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B
Adverse Reactions
Most common (>=10%) Infusion-related reaction, respiratory tract infection, viral infection, Type III hypersensitivity reaction, peripheral edema, headache
Serious Epistaxis, pneumonia, infusion-related reaction, pyelonephritis, COVID-19, hypovolemic shock, nasopharyngitis, urinary tract infection
Most common (>=10%) Injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, fatigue
Serious Infections, intestinal ischemia, biliary sepsis, hypersensitivity pneumonitis
Postmarketing Anaphylaxis, urticaria
Pharmacology
Crovalimab-akkz is a humanized IgG1 monoclonal antibody that binds with high affinity to complement protein C5, inhibiting its cleavage into C5a and C5b and preventing formation of the membrane attack complex (MAC), thereby inhibiting terminal complement-mediated intravascular hemolysis in patients with PNH.
C3 complement inhibitor; pegcetacoplan binds complement protein C3 and its activation fragment C3b, regulating downstream complement activation to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in PNH, and to inhibit C3 glomerular fragment deposition and C5b-9 assembly in C3G and primary IC-MPGN.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Piasky
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Empaveli
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Piasky
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Empaveli
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Piasky
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Empaveli
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableApellis Bridge Program: Empaveli
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PiaskyView full Piasky profile
EmpaveliView full Empaveli profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.